TKIhoito

TKIhoito refers to treatment utilizing tyrosine kinase inhibitors (TKIs). These are a class of targeted therapy drugs used primarily in cancer treatment. Unlike traditional chemotherapy which affects all rapidly dividing cells, TKIs specifically target proteins that play a role in cancer cell growth and survival.

The development of TKIs marked a significant advancement in precision medicine. By inhibiting the activity of specific tyrosine kinases, these drugs can block the signals that tell cancer cells to multiply and spread. This targeted approach often leads to fewer side effects compared to conventional chemotherapy, as healthy cells are less affected.

TKIs are used to treat a variety of cancers, including chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and certain types of gastrointestinal stromal tumors (GIST). Their effectiveness is often dependent on the presence of specific genetic mutations or protein alterations within the tumor.

The administration of TKIhoito is typically oral, meaning patients can often take their medication at home. However, like all medications, TKIs can have side effects, which can vary depending on the specific drug and the individual patient. Common side effects may include fatigue, skin rashes, diarrhea, and fluid retention. Monitoring by healthcare professionals is crucial to manage treatment and address any adverse effects. Research continues to expand the use of TKIs to other cancers and to develop new generations of these targeted agents.